{"transactions":[{"id":2102006,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Non-qualified stock option (right to buy)","published_at":"2022-12-01T01:33:01.000Z","date":"2022-11-28","kind":"grant","acquired":true,"shares":2315439,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"241,190 shares vested on November 28, 2022; the balance will vest on a monthly basis as follows (i) 48,238 shares at the conclusion of each month of Continuous Service (as the term is defined in the Issuer's 2012 Equity Incentive Plan, as amended), from November 2022 through February 2025, and (ii) 48,239 shares at the conclusion of each month of Continuous Service, from March 2025 through May 2026."}],"balance_after":2315439,"derivative":{"exercise_price":0.35,"expiration_date":"2032-11-28","underlying":"Common Stock","underlying_shares":2315439},"source":{"system":"sec-edgar","filing":"0001104659-22-123365","document":"tm2231600-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922123365/tm2231600-3_4seq1.xml","form_type":"4"}},{"id":2102005,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-12-01T01:33:01.000Z","date":"2022-11-30","kind":"grant","acquired":true,"shares":16927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2184037,"source":{"system":"sec-edgar","filing":"0001104659-22-123365","document":"tm2231600-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922123365/tm2231600-3_4seq1.xml","form_type":"4"}},{"id":2113822,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-11-17T23:51:35.000Z","date":"2022-11-15","kind":"grant","acquired":true,"shares":15234,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2167110,"source":{"system":"sec-edgar","filing":"0001104659-22-119979","document":"tm2230762-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922119979/tm2230762-2_4seq1.xml","form_type":"4"}},{"id":2128093,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-11-03T00:57:14.000Z","date":"2022-10-31","kind":"grant","acquired":true,"shares":17922,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2151876,"source":{"system":"sec-edgar","filing":"0001104659-22-114101","document":"tm2228860-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922114101/tm2228860-4_4seq1.xml","form_type":"4"}},{"id":2136055,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-10-18T20:02:38.000Z","date":"2022-10-15","kind":"grant","acquired":true,"shares":13849,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2133954,"source":{"system":"sec-edgar","filing":"0001104659-22-109687","document":"tm2228392-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922109687/tm2228392-1_4seq1.xml","form_type":"4"}},{"id":2146562,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-10-04T23:19:21.000Z","date":"2022-09-30","kind":"grant","acquired":true,"shares":18793,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in\nreporting person's cash salary."}],"balance_after":2120105,"source":{"system":"sec-edgar","filing":"0001104659-22-105980","document":"tm2227293-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922105980/tm2227293-1_4seq1.xml","form_type":"4"}},{"id":2156770,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-09-19T23:33:38.000Z","date":"2022-09-15","kind":"grant","acquired":true,"shares":9457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2101312,"source":{"system":"sec-edgar","filing":"0001104659-22-101258","document":"tm2226067-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922101258/tm2226067-3_4seq1.xml","form_type":"4"}},{"id":2168614,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-09-02T23:57:44.000Z","date":"2022-08-31","kind":"grant","acquired":true,"shares":11094,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2091855,"source":{"system":"sec-edgar","filing":"0001104659-22-097603","document":"tm2221304-7_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922097603/tm2221304-7_4seq1.xml","form_type":"4"}},{"id":2183245,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-08-17T20:02:32.000Z","date":"2022-08-15","kind":"grant","acquired":true,"shares":6950,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2080761,"source":{"system":"sec-edgar","filing":"0001104659-22-092174","document":"tm2221304-5_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922092174/tm2221304-5_4seq1.xml","form_type":"4"}},{"id":2195004,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-08-04T20:06:07.000Z","date":"2022-07-31","kind":"grant","acquired":true,"shares":7492,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2073811,"source":{"system":"sec-edgar","filing":"0001104659-22-086117","document":"tm2222420-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922086117/tm2222420-1_4seq1.xml","form_type":"4"}},{"id":2206019,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-07-19T20:02:27.000Z","date":"2022-07-15","kind":"grant","acquired":true,"shares":13112,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2066319,"source":{"system":"sec-edgar","filing":"0001104659-22-080836","document":"tm2221304-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922080836/tm2221304-1_4seq1.xml","form_type":"4"}},{"id":2216277,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-07-05T21:14:55.000Z","date":"2022-06-30","kind":"grant","acquired":true,"shares":13736,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2053207,"source":{"system":"sec-edgar","filing":"0001104659-22-077432","document":"tm2220248-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922077432/tm2220248-1_4seq1.xml","form_type":"4"}},{"id":2226322,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-21T20:45:07.000Z","date":"2022-06-15","kind":"grant","acquired":true,"shares":14423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2039471,"source":{"system":"sec-edgar","filing":"0001104659-22-073001","document":"tm2218921-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922073001/tm2218921-1_4seq1.xml","form_type":"4"}},{"id":2239773,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-08T20:08:03.000Z","date":"2022-05-31","kind":"grant","acquired":true,"shares":18029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2025048,"source":{"system":"sec-edgar","filing":"0001104659-22-069307","document":"tm2217755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922069307/tm2217755-4_4seq1.xml","form_type":"4"}},{"id":2239772,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-08T20:08:03.000Z","date":"2022-05-15","kind":"grant","acquired":true,"shares":16968,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":2007019,"source":{"system":"sec-edgar","filing":"0001104659-22-069307","document":"tm2217755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922069307/tm2217755-4_4seq1.xml","form_type":"4"}},{"id":2239771,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-08T20:08:03.000Z","date":"2022-04-30","kind":"grant","acquired":true,"shares":18029,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":1990051,"source":{"system":"sec-edgar","filing":"0001104659-22-069307","document":"tm2217755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922069307/tm2217755-4_4seq1.xml","form_type":"4"}},{"id":2239770,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-08T20:08:03.000Z","date":"2022-04-15","kind":"grant","acquired":true,"shares":21367,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":1972022,"source":{"system":"sec-edgar","filing":"0001104659-22-069307","document":"tm2217755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922069307/tm2217755-4_4seq1.xml","form_type":"4"}},{"id":2239769,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CMO"}}],"security":"Common Stock","published_at":"2022-06-08T20:08:03.000Z","date":"2022-03-31","kind":"grant","acquired":true,"shares":15592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents awards of fully vested shares under the issuer's 2012 Equity Incentive Plan approved by its Compensation Committee of the Board of Directors with a value on the respective date of grant equal to reduction in reporting person's cash salary."}],"balance_after":1950655,"source":{"system":"sec-edgar","filing":"0001104659-22-069307","document":"tm2217755-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000110465922069307/tm2217755-4_4seq1.xml","form_type":"4"}},{"id":2538585,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Non-qualified Stock Option","published_at":"2021-10-20T20:20:58.000Z","date":"2021-10-18","kind":"grant","acquired":true,"shares":1750000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in 3 equal annual installments beginning on August 6, 2022, subject to Continuous Service (as defined in the Issuer's 2012 Equity Incentive Plan, as amended) through the applicable vesting date."}],"balance_after":1750000,"derivative":{"exercise_price":1.39,"expiration_date":"2031-10-18","underlying":"Common Stock","underlying_shares":1750000},"source":{"system":"sec-edgar","filing":"0000899243-21-040761","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321040761/doc4.xml","form_type":"4"}},{"id":2609574,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common stock","published_at":"2021-08-10T22:40:22.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":153350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors."}],"balance_after":1935063,"source":{"system":"sec-edgar","filing":"0000899243-21-032395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321032395/doc4.xml","form_type":"4"}},{"id":2609573,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common stock","published_at":"2021-08-10T22:40:22.000Z","date":"2021-08-06","kind":"grant","acquired":true,"shares":40661,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors."}],"balance_after":1781713,"source":{"system":"sec-edgar","filing":"0000899243-21-032395","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924321032395/doc4.xml","form_type":"4"}},{"id":2878472,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Warrant (right to buy)","published_at":"2021-02-05T14:08:03.000Z","date":"2021-02-05","kind":"disposition_to_issuer","acquired":false,"shares":166000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2016-02-10","expiration_date":"2021-02-10","underlying":"Common Stock","underlying_shares":166666},"source":{"system":"sec-edgar","filing":"0001807094-21-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709421000001/primary_doc.xml","form_type":"4"}},{"id":2878471,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2021-02-05T14:08:03.000Z","date":"2021-02-05","kind":"exercise","acquired":true,"shares":166000,"price":0.75,"value":124500.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reporting person disclaims beneficial ownership of the shares held by his spouse and this report should not be deemed an admission that the reporting person is the beneficial owner of his spouse's shares for purposes of Section 16 or for any other purpose."}],"balance_after":782408,"source":{"system":"sec-edgar","filing":"0001807094-21-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709421000001/primary_doc.xml","form_type":"4"}},{"id":3017773,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Non-qualified Stock Option","published_at":"2020-10-02T22:18:03.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option grant was approved by a committee of the Issuer's Board of Directors on June 15, 2020, subject to stockholder approval of the Issuer's Amended & Restated 2012 Equity Incentive Plan (the \"Plan\") under which the option was granted. The Issuer's stockholders approved the Plan on September 30, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests annually in three equal installments beginning June 15, 2021."}],"balance_after":500000,"derivative":{"exercise_price":3.12,"expiration_date":"2030-06-15","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001807094-20-000018","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000018/primary_doc.xml","form_type":"4"}},{"id":3017772,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-10-02T22:18:03.000Z","date":"2020-09-30","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Amended & Restated 2012 Equity Incentive Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."}],"balance_after":1741052,"source":{"system":"sec-edgar","filing":"0001807094-20-000018","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000018/primary_doc.xml","form_type":"4"}},{"id":3043421,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-09-01T18:57:15.000Z","date":"2020-08-28","kind":"gift","acquired":true,"shares":74800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Custodian for daughter"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a gift of securities by the spouse of the reporting person to her daughter, who shares reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his spouse and his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of either his spouse's shares or his daughter's shares for purposes of Section 16 or for any other purpose."}],"balance_after":97980,"source":{"system":"sec-edgar","filing":"0001807094-20-000016","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000016/primary_doc.xml","form_type":"4"}},{"id":3043420,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-09-01T18:57:15.000Z","date":"2020-08-28","kind":"gift","acquired":false,"shares":74800,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a gift of securities by the spouse of the reporting person to her daughter, who shares reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his spouse and his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of either his spouse's shares or his daughter's shares for purposes of Section 16 or for any other purpose."}],"balance_after":616408,"source":{"system":"sec-edgar","filing":"0001807094-20-000016","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000016/primary_doc.xml","form_type":"4"}},{"id":3043419,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-09-01T17:46:57.000Z","date":"2019-08-09","kind":"gift","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Custodian for daughter"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose."}],"balance_after":97980,"source":{"system":"sec-edgar","filing":"0001807094-20-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000015/primary_doc.xml","form_type":"5"}},{"id":3043418,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-09-01T17:46:57.000Z","date":"2019-08-09","kind":"gift","acquired":false,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction involved a gift of securities by the reporting person to his daughter, who shares the reporting person's household. The reporting person disclaims beneficial ownership of the shares held by his daughter, and this report should not be deemed an admission that the reporting person is the beneficial owner of his daughter's shares for purposes of Section 16 or for any other purpose."}],"balance_after":1491052,"source":{"system":"sec-edgar","filing":"0001807094-20-000015","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000015/primary_doc.xml","form_type":"5"}},{"id":3148270,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option grant vests every four months beginning September 7, 2019."}],"balance_after":25000,"derivative":{"exercise_price":0.52,"exercise_date":"2020-03-01","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148269,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2020-04-07","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148268,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.385,"exercise_date":"2019-09-12","expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148267,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":66666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Option grant vests every four months beginning September 7, 2019."}],"balance_after":33334,"derivative":{"exercise_price":0.52,"exercise_date":"2020-03-01","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148266,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148265,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.49,"exercise_date":"2019-06-08","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148264,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":97009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":97009},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148263,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2018-06-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148262,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Nonqualified Stock Option-right to buy","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":7123,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.61,"exercise_date":"2017-05-31","expiration_date":"2027-04-10","underlying":"Common Stock","underlying_shares":7123},"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148261,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":8334,"price":0.52,"value":4333.68,"ownership":{"direct":true},"balance_after":1566052,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148260,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"sale","acquired":false,"shares":1200000,"price":3.2604,"value":3912480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $3.16 to $3.37. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1557718,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148259,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":93750,"price":0.39,"value":36562.5,"ownership":{"direct":true},"balance_after":2757718,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148258,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":750000,"price":0.385,"value":288750.0,"ownership":{"direct":true},"balance_after":2663968,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148257,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":66666,"price":0.52,"value":34666.32,"ownership":{"direct":true},"balance_after":1913968,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148256,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":250000,"price":0.565,"value":141250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This amendment to Form 4 filed on May 5, 2020 amends the transaction code to \"M\" from the original and incorrect transaction code of \"P.\" The transaction corresponds with the nonqualified option exercise on line 5 in Table II."}],"balance_after":1847302,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148255,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":100000,"price":0.49,"value":49000.0,"ownership":{"direct":true},"balance_after":1597302,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148254,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":97009,"price":0.56,"value":54325.04,"ownership":{"direct":true},"balance_after":1497302,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148253,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":75000,"price":0.57,"value":42750.0,"ownership":{"direct":true},"balance_after":1400293,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3148252,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chairman & CMO"}}],"security":"Common Stock","published_at":"2020-05-15T12:46:15.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":7123,"price":0.61,"value":4345.03,"ownership":{"direct":true},"balance_after":1325293,"source":{"system":"sec-edgar","filing":"0001807094-20-000007","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000007/primary_doc.xml","form_type":"4/A","original_submission_date":"2020-05-05"}},{"id":3162930,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-05","kind":"exercise","acquired":true,"shares":8334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option grant vests every four months beginning September 7, 2019."}],"balance_after":25000,"derivative":{"exercise_price":0.52,"exercise_date":"2020-03-01","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162929,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.39,"exercise_date":"2020-04-07","expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162928,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.385,"exercise_date":"2019-09-12","expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162927,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":66666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Option grant vests every four months beginning September 7, 2019."}],"balance_after":33334,"derivative":{"exercise_price":0.52,"exercise_date":"2020-03-01","expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":66666},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162926,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162925,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.49,"exercise_date":"2019-06-08","expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162924,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":97009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":97009},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162923,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2018-06-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162922,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Nonqualified Option - right to buy","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":7123,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.61,"exercise_date":"2017-05-31","expiration_date":"2027-04-10","underlying":"Common Stock","underlying_shares":7123},"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162921,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-04","kind":"exercise","acquired":true,"shares":8334,"price":0.52,"value":4333.68,"ownership":{"direct":true},"balance_after":1566052,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162920,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"sale","acquired":false,"shares":1200000,"price":3.2604,"value":3912480.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $3.16 to $3.37. The price above reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":1557718,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162919,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":93750,"price":0.39,"value":36562.5,"ownership":{"direct":true},"balance_after":2757718,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162918,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":750000,"price":0.385,"value":288750.0,"ownership":{"direct":true},"balance_after":2663968,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162917,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":66666,"price":0.52,"value":34666.32,"ownership":{"direct":true},"balance_after":1913968,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162916,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"purchase","acquired":true,"shares":250000,"price":0.565,"value":141250.0,"ownership":{"direct":true},"balance_after":1847302,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162915,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":100000,"price":0.49,"value":49000.0,"ownership":{"direct":true},"balance_after":1597302,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162914,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":97009,"price":0.56,"value":54325.04,"ownership":{"direct":true},"balance_after":1497302,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162913,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":75000,"price":0.57,"value":42750.0,"ownership":{"direct":true},"balance_after":1400293,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3162912,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2020-05-06T01:27:20.000Z","date":"2020-05-01","kind":"exercise","acquired":true,"shares":7123,"price":0.61,"value":4345.03,"ownership":{"direct":true},"balance_after":1325293,"source":{"system":"sec-edgar","filing":"0001807094-20-000006","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000180709420000006/primary_doc.xml","form_type":"4"}},{"id":3333305,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-12-24T00:02:14.000Z","date":"2019-12-19","kind":"grant","acquired":true,"shares":1250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"750,000 options vest immediately upon grant and 500,000 options vest upon the achievement of certain additional strategic milestones specified in the award agreement."}],"balance_after":1250000,"derivative":{"exercise_price":0.63,"expiration_date":"2029-12-19","underlying":"Common Stock","underlying_shares":1250000},"source":{"system":"sec-edgar","filing":"0000899243-19-029995","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319029995/doc4.xml","form_type":"4"}},{"id":3396381,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-10-08T23:03:04.000Z","date":"2019-10-07","kind":"grant","acquired":true,"shares":187500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments over the one year period commencing on January 7, 2020."}],"balance_after":187500,"derivative":{"exercise_price":0.39,"expiration_date":"2029-10-07","underlying":"Common Stock","underlying_shares":187500},"source":{"system":"sec-edgar","filing":"0000899243-19-025311","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319025311/doc4.xml","form_type":"4"}},{"id":3414578,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-09-16T21:13:15.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":750000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":750000,"derivative":{"exercise_price":0.385,"exercise_date":"2019-09-12","expiration_date":"2029-09-12","underlying":"Common Stock","underlying_shares":750000},"source":{"system":"sec-edgar","filing":"0000899243-19-023648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319023648/doc4.xml","form_type":"4"}},{"id":3485443,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2019-06-20T01:02:06.000Z","date":"2019-06-18","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest in four equal quarterly installments, commencing on September 1, 2019."}],"balance_after":100000,"derivative":{"exercise_price":0.52,"expiration_date":"2029-06-18","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-19-017510","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017510/doc4.xml","form_type":"4"}},{"id":3490746,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:13:53.000Z","date":"2019-06-12","kind":"exercise","acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2016-05-26","expiration_date":"2021-05-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-017092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017092/doc4.xml","form_type":"4"}},{"id":3490745,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:13:53.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":50000,"derivative":{"exercise_price":0.4,"exercise_date":"2016-05-26","expiration_date":"2021-05-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-017092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017092/doc4.xml","form_type":"4"}},{"id":3490744,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (Right to Buy)","published_at":"2019-06-14T22:13:53.000Z","date":"2019-06-12","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-26","expiration_date":"2021-05-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-19-017092","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017092/doc4.xml","form_type":"4"}},{"id":3490743,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:13:53.000Z","date":"2019-06-12","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On June 12, 2019, the Company completed a Warrant Tender Offer in which Dr. Kelly participated, among other non-affiliated investors, pursuant to which, as an inducement to immediately exercise certain warrants (the \"Warrants\") to purchase shares of the Company's common stock, par value $0.001 per share (\"Common Stock\") beneficially owned by Dr. Kelly, the Company (i) reduced the exercise price of such Warrants to $0.40 (if lower than the existing exercise price) and (ii) agreed to issue an additional one-half share of Common Stock for each share of Common Stock underlying the Warrants."}],"balance_after":1318170,"source":{"system":"sec-edgar","filing":"0000899243-19-017092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017092/doc4.xml","form_type":"4"}},{"id":3490742,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-06-14T22:13:53.000Z","date":"2019-06-12","kind":"exercise","acquired":true,"shares":50000,"price":0.4,"value":20000.0,"ownership":{"direct":true},"balance_after":1293170,"source":{"system":"sec-edgar","filing":"0000899243-19-017092","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319017092/doc4.xml","form_type":"4"}},{"id":3648555,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2019-02-20T23:28:29.000Z","date":"2019-02-16","kind":"grant","acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The warrant will vest in four equal quarterly installments commencing on May 16, 2019."}],"balance_after":500000,"derivative":{"exercise_price":0.51,"expiration_date":"2029-02-16","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0000899243-19-004306","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924319004306/doc4.xml","form_type":"4"}},{"id":3760368,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":166666,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":166666,"derivative":{"exercise_price":0.75,"exercise_date":"2016-02-10","expiration_date":"2021-02-10","underlying":"Common Stock","underlying_shares":166666},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760367,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":50000,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-26","expiration_date":"2021-05-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760366,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":250000,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760365,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options (including predecessor options) vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":100000,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760364,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":97009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":97009,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":97009},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760363,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":75000,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760362,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":7123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":7123,"derivative":{"exercise_price":0.61,"exercise_date":"2017-05-31","expiration_date":"2027-04-10","underlying":"Common Stock","underlying_shares":7123},"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760361,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":22980,"ownership":{"direct":false,"nature":"As Custodian for Daughter; See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":22980,"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760360,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":23180,"ownership":{"direct":false,"nature":"As Custodian for Daughter; See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":23180,"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760359,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":691208,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":691208,"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3760358,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-19T13:02:28.000Z","date":"2018-11-16","kind":"grant","acquired":true,"shares":1243170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":1243170,"source":{"system":"sec-edgar","filing":"0000899243-18-029259","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029259/doc4.xml","form_type":"4"}},{"id":3762708,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":166666,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.75,"exercise_date":"2016-02-10","expiration_date":"2021-02-10","underlying":"Common Stock","underlying_shares":166666},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762707,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":1.35,"exercise_date":"2016-05-26","expiration_date":"2021-05-26","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762706,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762705,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options vest in four equal quarterly installments commencing on September 1, 2018."}],"balance_after":0,"derivative":{"exercise_price":0.49,"expiration_date":"2028-06-08","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762704,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":97009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.56,"exercise_date":"2018-02-07","expiration_date":"2028-02-07","underlying":"Common Stock","underlying_shares":97009},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762703,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.57,"exercise_date":"2018-09-01","expiration_date":"2027-06-01","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762702,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":7123,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"derivative":{"exercise_price":0.61,"exercise_date":"2017-05-31","expiration_date":"2027-04-10","underlying":"Common Stock","underlying_shares":7123},"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762701,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":22980,"ownership":{"direct":false,"nature":"As Custodian for Daughter; See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762700,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":23180,"ownership":{"direct":false,"nature":"As Custodian for Daughter; See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reporting person disclaims beneficial ownership of the reported securities, and the inclusion of such securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762699,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":691208,"ownership":{"direct":false,"nature":"By Spouse"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3762698,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-11-16T23:39:27.000Z","date":"2018-11-16","kind":"disposition_to_issuer","acquired":false,"shares":1243170,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On November 16, 2018, CytoDyn Inc. completed a holding company reorganization in which CytoDyn Inc. (\"Old CytoDyn\") merged with and into a wholly-owned subsidiary of Point NewCo Inc. (which has been renamed CytoDyn Inc.) (\"New CytoDyn\") with Old CytoDyn continuing as the surviving corporation and as a wholly-owned subsidiary of New CytoDyn (the \"Holding Company Reorganization\"). In the Holding Company Reorganization, each outstanding share of Old CytoDyn capital stock (including common stock and Series B preferred stock) was disposed of in exchange for an equivalent share of New CytoDyn capital stock, and each Old CytoDyn warrant, convertible promissory note and stock option was converted into an equivalent right to purchase New CytoDyn common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In connection with the transactions consummated on November 16, 2018, immediately after the effective time of the Holding Company Reorganization, New CytoDyn issued to ProstaGene, LLC 27,000,000 newly issued shares of New CytoDyn common stock (representing approximately 6.5% of the total number of outstanding shares of New CytoDyn common stock, after giving effect to such issuance)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-029194","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318029194/doc4.xml","form_type":"4"}},{"id":3769028,"issuer":{"id":5856,"kind":"organization","name":"CytoDyn Inc."},"owners":[{"id":121995,"kind":"person","name":"Kelly Scott A.","position":1,"cik":"0001703394","reported_name":"Kelly Scott A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (right to buy)","published_at":"2018-11-13T21:32:34.000Z","date":"2018-11-08","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":250000,"derivative":{"exercise_price":0.565,"exercise_date":"2018-11-08","expiration_date":"2028-11-08","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000899243-18-028721","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1175680/000089924318028721/doc4.xml","form_type":"4"}}],"next_cursor":"2018-11-13T21:32:34.000000Z,3769028"}